Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $83.05, but opened at $75.88. Zealand Pharma A/S shares last traded at $75.88, with a volume of 150 shares changing hands.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 15th. Five equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Strong Buy”.

Zealand Pharma A/S Trading Up 1.7%

The business has a fifty day moving average price of $75.93 and a two-hundred day moving average price of $67.21. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $5.48 billion, a PE ratio of 5.55 and a beta of 0.72.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 62.52%. The firm had revenue of $7.76 million for the quarter, compared to analyst estimates of $4.54 million. Analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.